| 1.11 0.01 (0.91%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.39 |
1-year : | 1.55 |
| Resists | First : | 1.19 |
Second : | 1.33 |
| Pivot price | 1.17 |
|||
| Supports | First : | 0.97 |
Second : | 0.8 |
| MAs | MA(5) : | 1.09 |
MA(20) : | 1.16 |
| MA(100) : | 1.11 |
MA(250) : | 0.99 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13.5 |
D(3) : | 15.3 |
| RSI | RSI(14): 46.7 |
|||
| 52-week | High : | 2.04 | Low : | 0.41 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ADAP ] has closed above bottom band by 30.3%. Bollinger Bands are 6.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.17 - 1.17 | 1.17 - 1.18 |
| Low: | 1.09 - 1.09 | 1.09 - 1.1 |
| Close: | 1.1 - 1.11 | 1.11 - 1.12 |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Thu, 12 Sep 2024
Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions (NASDAQ:ADAP) - Seeking Alpha
Wed, 28 Aug 2024
Adaptimmune to Participate in Two Bank Conferences this September - StockTitan
Mon, 12 Aug 2024
Adaptimmune Therapeutics PLC (ADAP) Q2 2024 Earnings: EPS of $0. - GuruFocus.com
Mon, 12 Aug 2024
Earnings summary: Adaptimmune Therapeutics beats Q2 estimates (NASDAQ:ADAP) - Seeking Alpha
Mon, 12 Aug 2024
Adaptimmune Reports Q2 2024 Financial and Business Updates - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 256 (M) |
| Held by Insiders | 1.02e+009 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 7,130 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.288e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -51.3 % |
| Operating Margin | 53.5 % |
| Return on Assets (ttm) | -15.9 % |
| Return on Equity (ttm) | -65.1 % |
| Qtrly Rev. Growth | 2 % |
| Gross Profit (p.s.) | 181.63 |
| Sales Per Share | 6.43e+007 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -44 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -2.4 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 6.42 |
| Dividend | 0 |
| Forward Dividend | 6.83e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|